Back to Agenda
Oxford Debate: ‘This House Believes that Over-Engineered Clinical Development Has Inhibited Innovation’
Session Chair(s)
Julianne Hull, MS
CEO, WenStar Enterprises, United Kingdom
High-profile representatives from academia, industry, and patient organisations will debate both sides of this controversial hypothesis. Debaters will explore and argue the impact of regulations, budgets, quality, and patient needs.
Speaker(s)
Sir Martin Landray, PhD, FRCP
Chief Executive, Protas, United Kingdom
Debater
Michael Ryan
Vice President Strategic Accounts, Syneos Health, United Kingdom
Bettina Ryll
Member of the First EU Cancer Mission Board, MPNE, Vision Zero Cancer, Sweden
Debater
Sam Wadsworth, PhD
Chief Scientific Officer, Dimension Therapeutics, United States
Debater
Have an account?